Vertex Pharmaceuticals (VRTX) Peer Comparison
$549.04
$18.28
(3.44%)
As on 04-Nov-2026 16:11EST
Market cap
$141,654 Mln
Revenue (TTM)
$12,624 Mln
P/E Ratio
32.5
P/B Ratio
6.8
Div. Yield
0 %
Edit
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
141,654 | 95,531 | 88,519 | 44,890 | 41,005 |
Revenue ($ Mln) |
12,624 | 16,896 | 2,228 | 17,311 | -- |
Net Profit ($ Mln) |
4,405.20 | 4,817.40 | -3,151.00 | 1,394.00 | -1,768.29 |
Net Margin (%) |
34.89 | 28.51 | -141.43 | 8.05 | -- |
RoE (%) |
22.64 | 14.84 | -40.89 | 21.57 | -83.46 |
Price to Earnings |
32.55 | 23.24 | -- | 33.14 | -- |
Price-To-Book |
6.76 | 2.87 | 13.09 | 6.81 | 15.66 |
Income Statement ($ Mln)
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
12,624.30 | 16,896.20 | 2,228.00 | 17,311.00 | 0.00 |
|
Cost of Revenue
|
1,762.80 | 2,404.10 | 2,508.00 | 12,731.00 | 9.24 |
|
Gross Profit
|
10,267.50 | 12,242.20 | 1,076.00 | 5,430.00 | -16.56 |
|
Operating Expenses
|
5,989.90 | 9,500.60 | 3,040.00 | 2,256.00 | 1,618.01 |
|
Operating Profit (EBIT)
|
4,872.00 | 4,991.50 | -3,320.00 | 2,324.00 | -1,627.25 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
5,274.90 | 5,686.80 | -3,087.00 | 1,629.00 | -1,768.29 |
|
Provision for Tax
|
869.30 | 869.40 | 64.00 | 253.00 | 0.00 |
|
Profit after Tax (Net Income)
|
4,405.20 | 4,817.40 | -3,151.00 | 1,394.00 | -1,768.29 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -5.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 514.00 | 0.00 |
Liabilities ($ Mln)
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
20,247.90 | 33,498.50 | 6,761.00 | 6,660.00 | 2,606.24 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -5.00 | 0.00 |
|
Non-Current Liabilities
|
3,237.50 | 4,704.60 | 1,666.00 | 15,906.00 | 1,362.97 |
|
Current Liabilities
|
3,937.90 | 6,202.10 | 2,534.00 | 7,777.00 | 354.06 |
|
Total Liabilities
|
26,142.80 | 40,558.70 | 12,338.00 | 29,944.00 | 2,354.51 |
Assets ($ Mln)
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
14,879.60 | 23,610.10 | 5,146.00 | 24,023.00 | 294.93 |
|
Current Assets
|
12,543.70 | 20,795.10 | 5,815.00 | 6,451.00 | 4,028.34 |
|
Total Assets
|
26,142.80 | 40,558.70 | 12,338.00 | 29,944.00 | 2,354.51 |
|
Total Debt*
|
1,977.60 | 2,707.00 | 1,287.00 | 16,314.00 | 641.93 |
|
Net Current Assets
|
8,605.80 | 0.00 | 3,281.00 | -1,326.00 | 3,674.28 |
Cashflow ($ Mln)
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3,631.40 | 4,978.90 | -1,873.00 | 2,654.00 | -897.74 |
|
Cash Flow from Investing Activities
|
-945.40 | -629.10 | 1,946.00 | -2,305.00 | 118.06 |
|
Cash from Financing Activities
|
-2,261.30 | -3,715.40 | 593.00 | -150.00 | 621.52 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
19.42 | 13.65 | -25.41 | 6.34 | -53.99 |
|
ROE (%)
|
22.64 | 14.84 | -40.89 | 21.57 | -83.46 |
|
ROA (%)
|
14.80 | 8.78 | -23.27 | 3.69 | -48.50 |
|
EBIT Margin (%)
|
41.84 | 33.93 | -137.79 | 13.74 | -- |
|
Net Margin (%)
|
34.89 | 28.51 | -141.43 | 8.05 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
10.56 | 18.59 | -27.19 | 8.85 | -- |
|
EBIT Growth (%)
|
20.32 | 10.53 | -4.74 | 3.21 | -110.25 |
|
Net Profit Growth (%)
|
21.10 | 5.23 | -8.54 | 8.65 | -117.75 |
|
EPS Growth (%)
|
22.80 | 8.23 | -6.34 | 12.82 | -95.21 |
|
Book Value Growth (%)
|
19.36 | 9.85 | -29.52 | 11.16 | 24.65 |
Valuation Ratios
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
29.37 | 18.42 | -4.10 | 28.49 | -13.39 |
|
Price / Book Value
|
6.22 | 2.65 | 1.34 | 5.96 | 9.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
23.30 | 13.25 | -3.01 | 17.96 | -12.17 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.09 | 2.23 | 0.19 |
|
Short term debt to equity ratio
|
0.00 | 0.02 | 0.01 | 0.19 | 0.01 |
|
Current Ratio
|
3.19 | 3.35 | 2.29 | 0.83 | 11.38 |
|
Quick Ratio
|
2.74 | 2.89 | 2.18 | 0.83 | 11.38 |
|
Interest Coverage
|
800.23 | 122.77 | -72.50 | 3.08 | -28.80 |
Operating Efficiency Ratios
| Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.91 | 44.85 | 4.62 | 19.25 | -- |
|
Asset Turnover
|
0.42 | 0.31 | 0.16 | 0.46 | 0.00 |
|
Receivable days
|
55.39 | 152.19 | 82.29 | 74.65 | -- |
|
Inventory Days
|
292.28 | 546.66 | 56.81 | -- | -- |
|
Payable days
|
88.40 | 150.27 | 151.91 | 75.32 | 1,312.97 |
|
Cash Conversion Cycle
|
259.28 | 548.59 | -12.81 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
